Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Genomic Studies in Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders Show Alterations That Differ from Aggressive CD30-Positive T-Cell Lymphomas

Joo Y. Song, Weiwei Zhang, Michi M. Shinohara, Kord Honda, Christiane Querfeld, Julia Davidson, Krystie Chew, Lu Chen, Alexandra Hristov, Jasmine Zain, Anamarija M. Perry, Wing Chung Chan, Farah R Abdulla

Blood (2024) 144 (Supplement 1): 6225.

https://doi.org/10.1182/blood-2024-206611

Published: 2024

Journal Articles

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Blood (2024) 144 (Supplement 1): 3056.

https://doi.org/10.1182/blood-2024-200596

Published: 2024

Journal Articles

Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory/Advanced Cutaneous T Cell Lymphoma

Christiane Querfeld, Lu Chen, Xiwei Wu, Zhen Han, ChingYu Su, Melissa Banez, Jeralyn Quach, Tiffanie Barnhizer, Liliana Crisan, Steven T. Rosen, Jasmine Zain

Blood (2024) 144 (Supplement 1): 468.

https://doi.org/10.1182/blood-2024-205617

Published: 2024

Journal Articles

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

Christiane Querfeld, Lu Chen, Xiwei Wu, Zhen Han, ChingYu Su, Melissa Banez, Jeralyn Quach, Tiffanie Barnhizer, Liliana Crisan, Steven T. Rosen, Jasmine M. Zain

Blood (2023) 142 (Supplement 1): 3077.

https://doi.org/10.1182/blood-2023-188053

Published: 2023

Journal Articles

Quality of Life and Global Response Score in Cutaneous T-Cell Lymphoma

Niloufer Khan, Esther Drill, Alison Moskowitz, Michi M Shinohara, Cecilia Larocca, Christiane Querfeld, Jasmine M. Zain, Steven M. Horwitz

Blood (2023) 142 (Supplement 1): 381.

https://doi.org/10.1182/blood-2023-173713

Published: 2023

Journal Articles

Phase 1 Study of Autologous Sirpα-Low Macrophages (SIRPant-M) Administered By Intratumoral Injection Alone or in Combination with External-Beam Radiotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05967416)

Paolo Strati, Tatyana Feldman, Christiane Querfeld, Salvia Jain, Nathanael McCurley, Rita Bàrcia, Koby Kidder, Jelle Kylstra

Blood (2023) 142 (Supplement 1): 4856.

https://doi.org/10.1182/blood-2023-175040

Published: 2023

Journal Articles

Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia

Jonathan E. Brammer, Karen Ballen, Lubomir Sokol, Christiane Querfeld, Ryotaro Nakamura, Anjali Mishra, Eric M. McLaughlin, David Feith, Nazli Azimi, Thomas A. Waldmann, Yutaka Tagaya, Thomas Loughran

Blood (2023) 142 (15): 1271–1280.

https://doi.org/10.1182/blood.2022017643

Published: 2023

Includes: Supplemental data

Journal Articles

Receptor Targeted Delivery of the p38γ Inhibitor PIK-75 By Organic-Core Templated Lipid Nanoparticles in Cutaneous T Cell Lymphoma

Jonathan Scott Rink, Stephen E. Henrich, Alexandra Moxley, Xu Hannah Zhang, Xiwei Wu, SonBinh Nguyen, Christiane Querfeld, David A. Horne, Steve T. Rosen, Leo I. Gordon, Colby Shad Thaxton, Adam Yuh Lin

Blood (2022) 140 (Supplement 1): 4934–4935.

https://doi.org/10.1182/blood-2022-158864

Published: 2022

Journal Articles

Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

H. Miles Miles Prince, Larisa J Geskin, Oleg E Akilov, Timothy M. Kuzel, Christiane Querfeld, Chean Eng Ooi, Dongyuan Xing, Nicholas Sauter, Preeti Singh, Myron Czuczman, Francine M. Foss

Blood (2022) 140 (Supplement 1): 6577–6578.

https://doi.org/10.1182/blood-2022-167564

Published: 2022

Journal Articles

Blockade of the Immune Checkpoint CD47 By TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T Cell Lymphoma

Zhen Han, Xiwei Wu, Yate-Ching Yuan, Hanjun Qin, Chingyu Su, Jasmine Zain, Oleg E Akilov, Steve T Rosen, Mingye Feng, Christiane Querfeld

Blood (2022) 140 (Supplement 1): 6376–6377.

https://doi.org/10.1182/blood-2022-167670

Published: 2022

Journal Articles

Mechanisms of resistance to mogamulizumab

Christiane Querfeld

Blood (2022) 139 (26): 3674–3676.

https://doi.org/10.1182/blood.2022016594

Published: 2022

Journal Articles

Targeting macrophages for enhancing CD47 blockade–elicited lymphoma clearance and overcoming tumor-induced immunosuppression

Xu Cao, Yingyu Wang, Wencan Zhang, Xiancai Zhong, E. Gulsen Gunes, Jessica Dang, Jinhui Wang, Alan L. Epstein, Christiane Querfeld, Zuoming Sun, Steven T. Rosen, Mingye Feng

Blood (2022) 139 (22): 3290–3302.

https://doi.org/10.1182/blood.2021013901

Published: 2022

Includes: Supplemental data

Journal Articles

Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway

Blood (2021) 138 (23): 2435–2440.

https://doi.org/10.1182/blood.2021012536

Published: 2021

Includes: Supplemental data

Journal Articles

In Depth Analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm Based on a Comprehensive Literature Database of Cases

Robert S. Ohgami, Phyu Aung, Alejandro Ariel Gru, Mohammad O Hussaini, Christiane Querfeld, Kelou Yao, Corinn Small, Sumanth Gollapudi, David L Jaye, Sa A Wang, Sheeja T Pullarkat, Tracy I. George

Blood (2021) 138 (Supplement 1): 4383.

https://doi.org/10.1182/blood-2021-151694

Published: 2021

Journal Articles

Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders

Farah R Abdulla, Weiwei Zhang, Xiwei Wu, Kord Honda, Hanjun Qin, Hyejin Cho, Christiane Querfeld, Jasmine Zain, Steven T. Rosen, Wing C. Chan, Vishwas Parekh, Joo Y. Song

Blood (2021) 138 (Supplement 1): 4487.

https://doi.org/10.1182/blood-2021-152051

Published: 2021

Journal Articles

Tnfα Promotes an Immunosuppressive Microenvironment in Cutaneous T Cell Lymphoma and Regulates PD-L1 Expression

Emine Gulsen Gunes, PhD, Sung Hee Kil, PhD, Xiwei Wu, PhD, Chingyu Su, Zhen Han, Hanjun Qin, PhD, Ting-Fang He, PhD, Jing Chen, Yukiko Yamaguchi, PhD, Jasmine M. Zain, MD, Farah Abdulla, MD, Saul Priceman, PhD, Mingye Feng, PhD, Peter P. Lee, MD, Steven T. Rosen, MD, Christiane Querfeld, MDPhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-141070

Published: 2020

Journal Articles

Paired Single Cell RNA and TCR Sequencing Analysis Following PD-L1 Blockade in Cutaneous T-Cell Lymphoma

Christiane Querfeld, MDPhD, Xiwei Wu, PhD, Hanjun Qin, PhD, Chingyu Su, Zhen Han, Steven T. Rosen, MD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-139992

Published: 2020

Journal Articles

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Christiane Querfeld, MDPhD, Ni-Chun Tsai, MS, Joycelynne Palmer, PhD, Xochiquetzal U. Martinez, MD, Farah Abdulla, MD, Xiwei Wu, PhD, Steven T. Rosen, MD, Jasmine Zain, MD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-143354

Published: 2020

Journal Articles

The Involvement of STAT/SOCS Signaling in miRNA-Induced T Cell Exhaustion in Cutaneous T-Cell Lymphoma

Zhen Han, Chingyu Su, Renee J. Estephan, BS, Xiwei Wu, PhD, Sung Hee Kil, PhD, Steven T. Rosen, MD, Christiane Querfeld, MDPhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-139091

Published: 2020

Journal Articles

Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial

Christiane Querfeld, MDPhD, Basem M. William, MDMRCP, Lubomir Sokol, MD PhD, Oleg Akilov, MD, Brian Poligone, MD PhD, Jasmine Zain, MD, Yutaka Tagaya, MD PhD, Nazli Azimi, PhD PharmD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-143135

Published: 2020

NARROW

Genomic Studies in Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders Show Alterations That Differ from Aggressive CD30-Positive T-Cell Lymphomas

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory/Advanced Cutaneous T Cell Lymphoma

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

Quality of Life and Global Response Score in Cutaneous T-Cell Lymphoma

Phase 1 Study of Autologous Sirpα-Low Macrophages (SIRPant-M) Administered By Intratumoral Injection Alone or in Combination with External-Beam Radiotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05967416)

Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia

Receptor Targeted Delivery of the p38γ Inhibitor PIK-75 By Organic-Core Templated Lipid Nanoparticles in Cutaneous T Cell Lymphoma

Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Blockade of the Immune Checkpoint CD47 By TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T Cell Lymphoma

Mechanisms of resistance to mogamulizumab

Targeting macrophages for enhancing CD47 blockade–elicited lymphoma clearance and overcoming tumor-induced immunosuppression

Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway

In Depth Analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm Based on a Comprehensive Literature Database of Cases

Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders

Tnfα Promotes an Immunosuppressive Microenvironment in Cutaneous T Cell Lymphoma and Regulates PD-L1 Expression

Paired Single Cell RNA and TCR Sequencing Analysis Following PD-L1 Blockade in Cutaneous T-Cell Lymphoma

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

The Involvement of STAT/SOCS Signaling in miRNA-Induced T Cell Exhaustion in Cutaneous T-Cell Lymphoma

Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only